Cargando…
Efficacy of Paxlovid in patients with acute kidney injury who developed COVID-19
Autores principales: | Cai, Hong, Yan, Jiayi, Wang, Jieying, Che, Xiajing, Mou, Shan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The British Infection Association. Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546778/ https://www.ncbi.nlm.nih.gov/pubmed/36220502 http://dx.doi.org/10.1016/j.jinf.2022.10.002 |
Ejemplares similares
-
Paxlovid for hospitalized COVID-19 patients with chronic kidney disease
por: Cai, Hong, et al.
Publicado: (2023) -
Efficacy and safety of Paxlovid for COVID-19:a meta-analysis
por: Zheng, Qian, et al.
Publicado: (2023) -
Elevated troponin levels predict the reduced efficacy of Paxlovid in COVID-19 patients
por: Zhao, Deze, et al.
Publicado: (2023) -
Nirmatrelvir/ritonavir for patients with SARS-CoV-2 infection and impaired kidney function during the Omicron surge
por: Yan, Jiayi, et al.
Publicado: (2023) -
Association between the levels of urine kidney injury molecule-1 and the progression of acute kidney injury in the elderly
por: Xie, Yuanyuan, et al.
Publicado: (2017)